North America Vaccine Adjuvants Market Forecast to 2030 - Regional Analysis - by Adjuvant Class (Mineral Salt Adjuvant, Emulsion Adjuvant, Liposome Adjuvant, and Others) and Type (Human Vaccine Adjuvant and Veterinary Vaccine Adjuvant)

Description

List of Tables

The North America vaccine adjuvants market was valued at US$ 1,044.84 million in 2022 and is expected to reach US$ 2,862.04 million by 2030; it is estimated to register a CAGR of 13.4% from 2022 to 2030 .

Rising Number of Infectious Disease Outbreaks and Pandemic Fuels North America Vaccine Adjuvants Market

According to the World Bank 2023 report, bacterial, viral, parasite, or fungal diseases can be contagious, spreading directly from person to person or animal to person. As per the National Institute of Health (NIH) report, the H1N1 influenza pandemic resulted in losses of ~US$ 2.8 billion to the Mexican tourism industry, as the footfall of tourists decreased by nearly 1 million over a 5-month window of the contagious spread of H1N1 virus. The Mexican state of Texcoco reported an outbreak of low pathogenicity avian influenza (LPAI) A(H5N2) in March 2024, and Temascalapa municipality in the same state reported another outbreak in April. Additionally, in the state of Michoacan, a private poultry farm detected a high-pathogenicity avian influenza A(H5N2) outbreak that was discovered in March 2024. In 2022, it was reported that both LPAI and HPAI A(H5) subtypes have been found in bird species in Mexico, both recently and in the past. Although they typically infect animals, animal influenza viruses can also infect people. Human infections have mostly been contracted via close contact with animals that are infected or contaminated environments. Influenza A viruses can be categorized as avian influenza, swine influenza, or other animal influenza viruses based on their original host. Therefore, the emergence of various infectious diseases with the associated cost burden accelerates the manufacturers' demand for vaccines and vaccine adjuvants.

COVAXIN, a vaccine developed by Bharat Biotech to fight against the COVID-19 pandemic, uses Alhydroxiquim-II as an adjuvant. The biotech company ViroVax LLC discovered and tested this adjuvant in the laboratory. The pharmacological action of Alhydroxiquim-II is that it travels through lymph nodes and activates TLR7 and TLR8 cellular receptors, which play a vital role in the immune response against viruses. Alhydroxiquim-II is the first adjuvant responsible for activating TLR7 and TLR8, thus stimulating people's immune responses. Therefore, the rising number of infectious disease outbreaks and pandemics, accounting for high healthcare costs, propels the demand for vaccine adjuvants.

North America Vaccine Adjuvants Market Overview

The North America vaccine adjuvants market has been segmented into the US, Canada, and Mexico. Fast product approval processes benefit the vaccine adjuvants market in the US. In May 2023, GlaxoSmithKline (GSK) won US Food and Drug Administration (FDA) approval for its Arexvy (respiratory syncytial virus vaccine, adjuvanted) vaccine intended for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV). Thus, Arexvy became the world's first FDA-approved RSV vaccine for older adults. In October 2022, Novavax, Inc. received an Emergency Use Authorization (EUA) from the FDA for its COVID-19 adjuvanted vaccine, indicated as a booster for adult patients.

North America Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)

North America Vaccine Adjuvants Market Segmentation

The North America vaccine adjuvants market is categorized into adjuvant class, type, and country.

Based on adjuvant class, the North America vaccine adjuvants market is segmented into mineral salt adjuvant, emulsion adjuvant, liposome adjuvant, and others. The mineral salt adjuvant segment held the largest share of the North America vaccine adjuvants market share in 2022.

By type, the North America vaccine adjuvants market is bifurcated into human vaccine adjuvant and veterinary vaccine adjuvant. The human vaccine adjuvant segment held a larger share of North America vaccine adjuvants market in 2022.

By country, the North America vaccine adjuvants market is segmented into the US, Canada, and Mexico. The US dominated the North America vaccine adjuvants market share in 2022.

Croda International Plc; CSL Ltd; Dynavax Technologies Corp; GSK Plc; Hawaii Biotech Inc; InvivoGen SAS; Novavax Inc; Phibro Animal Health Corp; Seppic SA; and SPI Pharma Inc are some of the leading companies operating in the North America vaccine adjuvants market.

Product Code: BMIRE00031087

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Vaccine Adjuvants Market - Key Market Dynamics

4.1 North America Vaccine Adjuvants Market - Key Market Dynamics
4.2 Market Drivers
- 4.2.1 Rising Number of Infectious Disease Outbreaks and Pandemic
- 4.2.2 Approvals of Veterinary Vaccine Adjuvants
4.3 Market Restraints
- 4.3.1 Product Recalls and Adverse Effects
4.4 Market Opportunities
- 4.4.1 Support for Developments in Adjuvant Studies and Collaborative Efforts for Product Launches
- 4.4.2 Advancements in Biotechnology and Immunology
4.5 Future Trends
- 4.5.1 Technological Advancements
4.6 Impact of Drivers and Restraints:

5. Vaccine Adjuvants Market -North America Analysis

5.1 North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
5.2 North America Vaccine Adjuvants Market Forecast and Analysis

6. North America Vaccine Adjuvants Market Analysis - by Adjuvant Class

6.1 Overview
6.2 Mineral Salt Adjuvant
- 6.2.1 Overview
- 6.2.2 Mineral Salt Adjuvant: North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Emulsion Adjuvant
- 6.3.1 Overview
- 6.3.2 Emulsion Adjuvant: North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Liposome Adjuvant
- 6.4.1 Overview
- 6.4.2 Liposome Adjuvant: North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Others
- 6.5.1 Overview
- 6.5.2 Others: North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7. North America Vaccine Adjuvants Market Analysis - by Type

7.1 Human Vaccine Adjuvant
- 7.1.1 Overview
- 7.1.2 Human Vaccine Adjuvant: North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.2 Veterinary Vaccine Adjuvant
- 7.2.1 Overview
- 7.2.2 Veterinary Vaccine Adjuvant: North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Vaccine Adjuvants Market -Country Analysis

8.1 North America
- 8.1.1 North America Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
  - 8.1.1.1 United States: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.1.1 Overview
    - 8.1.1.1.2 United States: Glucose Monitoring Devices Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.1.3 United States: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
    - 8.1.1.1.4 United States: Vaccine Adjuvants Market Breakdown, by Type
  - 8.1.1.2 Canada: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.2.1 Overview
    - 8.1.1.2.2 Canada: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.2.3 Canada: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
    - 8.1.1.2.4 Canada: Vaccine Adjuvants Market Breakdown, by Type
  - 8.1.1.3 Mexico: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.3.1 Overview
    - 8.1.1.3.2 Mexico: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.3.3 Mexico: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
    - 8.1.1.3.4 Mexico: Vaccine Adjuvants Market Breakdown, by Type

9. Industry Landscape

9.1 Overview
9.2 Growth Strategies in the Global Vaccine Adjuvants Market
9.3 Organic Developments
- 9.3.1 Overview
9.4 Inorganic Developments
- 9.4.1 Overview

10. Company Profiles

10.1 SPI Pharma Inc
- 10.1.1 Key Facts
- 10.1.2 Business Description
- 10.1.3 Products and Services
- 10.1.4 Financial Overview
- 10.1.5 SWOT Analysis
- 10.1.6 Key Developments
10.2 GSK Plc
- 10.2.1 Key Facts
- 10.2.2 Business Description
- 10.2.3 Products and Services
- 10.2.4 Financial Overview
- 10.2.5 SWOT Analysis
- 10.2.6 Key Developments
10.3 CSL Ltd
- 10.3.1 Key Facts
- 10.3.2 Business Description
- 10.3.3 Products and Services
- 10.3.4 Financial Overview
- 10.3.5 SWOT Analysis
- 10.3.6 Key Developments
10.4 Seppic SA
- 10.4.1 Key Facts
- 10.4.2 Business Description
- 10.4.3 Products and Services
- 10.4.4 Financial Overview
- 10.4.5 SWOT Analysis
- 10.4.6 Key Developments
10.5 Hawaii Biotech Inc
- 10.5.1 Key Facts
- 10.5.2 Business Description
- 10.5.3 Products and Services
- 10.5.4 Financial Overview
- 10.5.5 SWOT Analysis
- 10.5.6 Key Developments
10.6 Dynavax Technologies Corp
- 10.6.1 Key Facts
- 10.6.2 Business Description
- 10.6.3 Products and Services
- 10.6.4 Financial Overview
- 10.6.5 SWOT Analysis
- 10.6.6 Key Developments
10.7 InvivoGen SAS
- 10.7.1 Key Facts
- 10.7.2 Business Description
- 10.7.3 Products and Services
- 10.7.4 Financial Overview
- 10.7.5 SWOT Analysis
- 10.7.6 Key Developments
10.8 Croda International Plc
- 10.8.1 Key Facts
- 10.8.2 Business Description
- 10.8.3 Products and Services
- 10.8.4 Financial Overview
- 10.8.5 SWOT Analysis
- 10.8.6 Key Developments
10.9 Novavax Inc
- 10.9.1 Key Facts
- 10.9.2 Business Description
- 10.9.3 Products and Services
- 10.9.4 Financial Overview
- 10.9.5 SWOT Analysis
- 10.9.6 Key Developments
10.10 Phibro Animal Health Corp
- 10.10.1 Key Facts
- 10.10.2 Business Description
- 10.10.3 Products and Services
- 10.10.4 Financial Overview
- 10.10.5 SWOT Analysis
- 10.10.6 Key Developments

11. Appendix

11.1 About The Insight Partners